Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401. doi: 10.1128/AAC.01326-16. Print 2016 Oct.

Abstract

TROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.

Publication types

  • Validation Study

MeSH terms

  • Cyclohexanes / pharmacology*
  • HIV / drug effects*
  • HIV / physiology
  • HIV Fusion Inhibitors / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Maraviroc
  • Triazoles / pharmacology*
  • Viral Tropism / drug effects*
  • Viral Tropism / physiology
  • Virology / methods*

Substances

  • Cyclohexanes
  • HIV Fusion Inhibitors
  • Triazoles
  • Maraviroc

Grants and funding

This work was supported by Redes Telemáticas de Investigación Cooperativa en Salud (RETICS; 2006, Red de SIDA RD06/0006/0021, 2007–2010, and RD16/0025/0020) and Pfizer/ViiV Healthcare (grants WS843473 and WS2425049).